Lundbeck’s sales Rise with antidepressants and migraine Drugs
Danish pharmaceutical company Lundbeck reports increased sales and profit in the first quarter of the year. The total revenue for the quarter is approximately 5.3 billion DKK, a 7% increase in constant currency compared to the same period last year. The company’s profit reached 1 billion DKK, up by 14%. Particularly, the sales of key drugs like Brintellix/Trintellix, used for treating adult depression, rose by 11% in constant currency, making 1.17 billion DKK in sales. This drug saw increased sales in all regions, with notable demand in Spain. Additionally, migraine medication Vyepti’s sales surged by 79%, amounting to 617 million DKK. Launched in the US in April 2020, Vyepti has expanded to around 25 markets. Lundbeck expects a 7-10% revenue growth for 2024 in constant currency and a slightly lower rate in Danish kroner. The company foresees continued strong Vyepti sales in the USA and further global expansion.